“Tirzepatide does not currently have FDA approval for cardiac risk reduction, and thus, coverage and usage are limited to patients with type 2 diabetes, obesity, and obstructive sleep apnea,” said David Rhee, MD, board certified cardiologist with Manhattan Cardiology in NYC, who wasn’t involved in the study.
Mounjaro is currently only approved for the treatment of type 2 diabetes.
Zepbound has the same active ingredient, tirzepatide, and is
If you have questions about GLP-1 medications and how they may help improve your health, speak with a healthcare professional.
Leave a Reply